Trials / Terminated
TerminatedNCT04245722
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- Fate Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FT596 | Experimental Interventional Therapy |
| DRUG | Cyclophosphamide | Lympho-conditioning agent |
| DRUG | Fludarabine | Lympho-conditioning agent |
| DRUG | Rituximab | Monoclonal Antibody |
| DRUG | Obinutuzumab | Monoclonal Antibody |
| DRUG | Bendamustine | Conditioning agent |
Timeline
- Start date
- 2020-03-19
- Primary completion
- 2023-09-27
- Completion
- 2023-09-27
- First posted
- 2020-01-29
- Last updated
- 2023-10-26
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04245722. Inclusion in this directory is not an endorsement.